Evidence map›Paper›PMID 40400768›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025

Lipoprotein(a) as a Risk Factor for Recurrent Ischemic Stroke in Type 2 Diabetes.

Ruomeng Chen, Kun Zhang, Hui Liu, Lijuan Liu, Hui Li, Yan Yan, Zhou Zhou, Chaoyue Meng, Xuelin Wang, Haoran Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ruomeng ChenDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Kun ZhangDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Hui LiuDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Lijuan LiuDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Hui LiDepartment of Neurology, Hengshui People's Hospital, Hengshui City, Hebei Province, People's Republic of China.
Yan YanDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Zhou ZhouDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Chaoyue MengDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Xuelin WangDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Haoran WuDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Ruihan MiaoDepartment of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Rui WangDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.
Xiaoyun LiuDepartment of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.ORCID 0009-0003-8604-904X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the effect of LP(a) on recurrent ischemic stroke among persons with and without diabetes, providing a basis for the precise management of patients with recurrent ischemic stroke with diabetes in clinical practice. Methods: This study was conducted on consecutive patients with cerebral infarction diagnosed between January 2019 and March 2023 in the Second Hospital of Hebei Medical University. Stratified analyses were performed according to LP(a) level (≤/>90th percentile) and logistic regression modeling was performed to investigate the relationship between LP(a) and recurrent ischemic stroke with or without T2DM. Results: In the final enrollment of 2029 patients, the number of recurrent ischemic stroke according to LP(a) >90th percentile combined with T2DM was 59.15%, which was significantly higher than in LP(a) ≤90th percentile combined with T2DM (46.17%, Conclusion: LP(a) is an independent risk factor for recurrent ischemic stroke in the diabetic population but not in nondiabetic individuals. Simple categorization based on the presence or absence of comorbid T2DM significantly influences the association between LP(a) and recurrent ischemic stroke. Therefore, in clinical practice, for ischemic stroke patients with comorbid diabetes, the LP(a) level should be more strictly controlled.

Indexed as

lipoprotein(a)recurrent ischemic stroketype 2 diabetes mellitus

Identifiers

PMID40400768
PMCPMC12094477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.